Other studies are under way now to investigate the efficacy of targeting the IL-33 pathway in asthma including melrilimab, which inhibits ST2, and tozorakimab, a phase II study with anti-IL-33 which has been completed and the data are currently under analysis. This evidence concerns the gene IL33 and asthma.